You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCarisoprodol
Accession NumberDB00395  (APRD00417)
TypeSmall Molecule
GroupsApproved
DescriptionA centrally acting skeletal muscle relaxant whose mechanism of action is not completely understood but may be related to its sedative actions. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1202)
Structure
Thumb
Synonyms
(+-)-2-Methyl-2-propyl-1,3-propanediol carbamate isopropylcarbamate
(1-Methylethyl)carbamic acid 2-(((aminocarbonyl)oxy)methyl)-2-methylpentyl ester
(RS)-2-{[(aminocarbonyl)oxy]methyl}-2-methylpentyl isopropylcarbamate
2-Methyl-2-propyl-1,3-propanediol carbamate isopropylcarbamate
2-Methyl-2-propyltrimethylene carbamate isopropylcarbamate
Carbamic acid 2-isopropylcarbamoyloxymethyl-2-methyl-pentyl ester
Carisoprodate
Carisoprodol
Carisoprodolum
Isobamate
Isomeprobamate
Isopropyl meprobamate
Isopropylmeprobamate
N-Isopropy-2-methyl-2-propyl-1,3-propanediol dicarbamate
Someprobamate
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Carisoprodoltablet250 mg/1oralWallace Pharmaceuticals Inc.2010-07-01Not applicableUs
Somatablet350 mg/1oralMeda Pharmaceuticals Inc.1959-07-01Not applicableUs
Somatablet250 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2007-09-01Not applicableUs
Somatablet250 mg/1oralMeda Pharmaceuticals Inc.2007-09-01Not applicableUs
Somatablet250 mg/1oralSTAT Rx USA LLC2007-09-01Not applicableUs
Somatablet250 mg/1oralRebel Distributors Corp2007-09-01Not applicableUs
Soma Tablets 350mgtablet350 mgoralCarter Horner Corp.1962-12-312003-03-14Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Carisoprodoltablet350 mg/1oralA S Medication Solutions Llc2007-02-27Not applicableUs
Carisoprodoltablet350 mg/1oralDIRECT RX2014-01-01Not applicableUs
Carisoprodoltablet350 mg/1oralPreferred Pharmaceuticals, Inc.2011-06-15Not applicableUs
Carisoprodoltablet350 mg/1oralSTAT Rx USA LLC1996-01-24Not applicableUs
Carisoprodoltablet350 mg/1oralWest Ward Pharmaceuticals Corp1996-01-24Not applicableUs
Carisoprodoltablet350 mg/1oralVensun Pharmaceuticals, Inc.2014-07-31Not applicableUs
Carisoprodoltablet350 mg/1oralA S Medication Solutions Llc1997-09-08Not applicableUs
Carisoprodoltablet350 mg/1oralRising Pharmaceuticals, Inc.2010-07-01Not applicableUs
Carisoprodoltablet350 mg/1oralDIRECT RX2016-04-01Not applicableUs
Carisoprodoltablet350 mg/1oralMirror Pharmaceuticals LLC2011-08-22Not applicableUs
Carisoprodoltablet350 mg/1oralbryant ranch prepack1997-09-08Not applicableUs
Carisoprodoltablet350 mg/1oralLife Line Home Care Services, Inc1987-11-01Not applicableUs
Carisoprodoltablet350 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC1996-01-24Not applicableUs
Carisoprodoltablet350 mg/1oralREMEDYREPACK INC.2013-04-03Not applicableUs
Carisoprodoltablet350 mg/1oralCardinal Health2010-10-08Not applicableUs
Carisoprodoltablet350 mg/1oralAphena Pharma Solutions Tennessee, Llc1997-09-08Not applicableUs
Carisoprodoltablet350 mg/1oralBlenheim Pharmacal, Inc.2011-02-02Not applicableUs
Carisoprodoltablet350 mg/1oralAidarex Pharmaceuticals LLC2010-08-30Not applicableUs
Carisoprodoltablet350 mg/1oralScie Gen Pharmaceuticals, Inc.2014-01-27Not applicableUs
Carisoprodoltablet350 mg/1oralSun Pharmaceutical Industries Limited2007-02-27Not applicableUs
Carisoprodoltablet350 mg/1oralPreferred Pharmaceuticals, Inc.2013-11-13Not applicableUs
Carisoprodoltablet350 mg/1oralWest ward Pharmaceutical Corp1996-01-24Not applicableUs
Carisoprodoltablet350 mg/1oralSTAT Rx USA LLC1996-01-24Not applicableUs
Carisoprodoltablet350 mg/1oralPhysicians Total Care, Inc.1996-04-04Not applicableUs
Carisoprodoltablet350 mg/1oralAurobindo Pharma Limited2009-08-06Not applicableUs
Carisoprodoltablet350 mg/1oralH.J. Harkins Company, Inc.1996-01-24Not applicableUs
Carisoprodoltablet350 mg/1oralbryant ranch prepack1997-09-08Not applicableUs
Carisoprodoltablet350 mg/1oralOrient Pharma Co., Ltd.2015-06-01Not applicableUs
Carisoprodoltablet350 mg/1oralLake Erie Medical DBA Quality Care Products LLC2007-02-27Not applicableUs
Carisoprodoltablet350 mg/1oralREMEDYREPACK INC.2013-05-09Not applicableUs
Carisoprodoltablet350 mg/1oralPd Rx Pharmaceuticals, Inc.1987-11-01Not applicableUs
Carisoprodoltablet350 mg/1oralAmerican Health Packaging2010-01-15Not applicableUs
Carisoprodoltablet350 mg/1oralBlenheim Pharmacal, Inc.2012-10-15Not applicableUs
Carisoprodoltablet350 mg/1oralRx Change Co.2010-07-01Not applicableUs
Carisoprodoltablet350 mg/1oralUnit Dose Services2007-02-27Not applicableUs
Carisoprodoltablet350 mg/1oralProficient Rx LP2014-06-01Not applicableUs
Carisoprodoltablet350 mg/1oralPreferred Pharmaceuticals, Inc.2015-05-01Not applicableUs
Carisoprodoltablet350 mg/1oralDispensing Solutions, Inc.1997-09-08Not applicableUs
Carisoprodoltablet350 mg/1oralWatson Laboratories, Inc.1987-11-01Not applicableUs
Carisoprodoltablet350 mg/1oralPd Rx Pharmaceuticals, Inc.1997-09-08Not applicableUs
Carisoprodoltablet350 mg/1oralDispensing Solutions, Inc.1997-09-08Not applicableUs
Carisoprodoltablet350 mg/1oralMutual Pharmaceutical Company, Inc.1991-10-17Not applicableUs
Carisoprodoltablet350 mg/1oralbryant ranch prepack1987-11-01Not applicableUs
Carisoprodoltablet350 mg/1oralApotheca Inc.1991-10-17Not applicableUs
Carisoprodoltablet350 mg/1oralRebel Distributors Corp2007-02-27Not applicableUs
Carisoprodoltablet350 mg/1oralA S Medication Solutions Llc2007-02-27Not applicableUs
Carisoprodoltablet350 mg/1oralGolden State Medical Supply, Inc.2014-02-20Not applicableUs
Carisoprodoltablet350 mg/1oralKeltman Pharmaceuticals Inc.2007-08-10Not applicableUs
Carisoprodoltablet350 mg/1oralBlenheim Pharmacal, Inc.2011-01-31Not applicableUs
Carisoprodoltablet350 mg/1oralProficient Rx LP1997-09-08Not applicableUs
Carisoprodoltablet350 mg/1oralBionpharma Inc.2015-04-01Not applicableUs
Carisoprodoltablet350 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC1987-11-01Not applicableUs
Carisoprodoltablet350 mg/1oralNorthwind Pharmaceuticals2014-06-01Not applicableUs
Carisoprodoltablet350 mg/1oralMedsource Pharmaceuticals2007-02-27Not applicableUs
Carisoprodoltablet350 mg/1oralCardinal Health2010-01-15Not applicableUs
Carisoprodoltablet350 mg/1oralRed Pharm Drug Inc.1997-09-08Not applicableUs
Carisoprodoltablet350 mg/1oralQualitest Pharmaceuticals1997-09-08Not applicableUs
Carisoprodoltablet350 mg/1oralA S Medication Solutions Llc1997-09-08Not applicableUs
Carisoprodoltablet350 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation1997-09-08Not applicableUs
Carisoprodoltablet350 mg/1oralCarlsbad Technology, Inc.2014-01-27Not applicableUs
Carisoprodol Immediate Releasetablet250 mg/1oralVensun Pharmaceuticals, Inc2015-11-20Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CarisomaNot Available
GencariGenovate
GenesafeGenovate
HiraninHwang's
ListaflexFinadiet
SanomaNot Available
TensaprinNewport
Brand mixtures
NameLabellerIngredients
Carisoprodol and AspirinEon Labs, Inc.
Carisoprodol, Aspirin and Codeine PhosphateEon Labs, Inc.
SaltsNot Available
Categories
UNII21925K482H
CAS number78-44-4
WeightAverage: 260.33
Monoisotopic: 260.173607266
Chemical FormulaC12H24N2O4
InChI KeyInChIKey=OFZCIYFFPZCNJE-UHFFFAOYSA-N
InChI
InChI=1S/C12H24N2O4/c1-5-6-12(4,7-17-10(13)15)8-18-11(16)14-9(2)3/h9H,5-8H2,1-4H3,(H2,13,15)(H,14,16)
IUPAC Name
2-[(carbamoyloxy)methyl]-2-methylpentyl N-(propan-2-yl)carbamate
SMILES
CCCC(C)(COC(N)=O)COC(=O)NC(C)C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as monocarboxylic acids and derivatives. These are carboxylic acids containing exactly one carboxyl groups.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassMonocarboxylic acids and derivatives
Direct ParentMonocarboxylic acids and derivatives
Alternative Parents
Substituents
  • Monocarboxylic acid or derivatives
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the relief of discomfort associated with acute, painful, musculoskeletal conditions.
PharmacodynamicsCarisoprodol is used as a skeletal muscle relaxant. One of its metabolites, meprobamate, is available as an anxiolytic agent.
Mechanism of actionCarisoprodol is a central nervous system depressant that acts as a sedative and skeletal muscle relaxant. Rather than acting directly on skeletal muscle, carisoprodol interrupts neuronal communication within the reticular formation and spinal cord, resulting in sedation and alteration in pain perception. Its exact mechanism of action is not yet known.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding60%
Metabolism

Hepatic. Metabolized in the liver via the cytochrome P450 oxidase isozyme CYP2C19.

Route of eliminationCarisoprodol is eliminated by both renal and non-renal routes.
Half life8 hours
Clearance
  • oral cl=0.772 L/hour/kg [Women]
  • oral cl=0.38 L/hour/kg [Men]
ToxicitySymptoms of overdose include drowsiness, giddiness, nausea, indigestion, or rash. Other adverse effects attributed to therapeutic use of carisoprodol include dizziness, irritability, insomnia, diplopia, temporary loss of vision, ataxia, weakness, headache, and dysarthria. Non-CNS adverse effects include gastrointestinal complaints, tachycardia, and postural hypotension. Patients sensitive to sulfites or tartrazine may experience wheezing, allergic rashes including erythema multiforme, or anaphylaxis after using some preparations of carisoprodol which contain such additives
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9626
Blood Brain Barrier+0.9679
Caco-2 permeable-0.5533
P-glycoprotein substrateSubstrate0.5
P-glycoprotein inhibitor INon-inhibitor0.8014
P-glycoprotein inhibitor IINon-inhibitor0.8381
Renal organic cation transporterNon-inhibitor0.9519
CYP450 2C9 substrateNon-substrate0.9041
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6418
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8659
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.6872
BiodegradationNot ready biodegradable0.973
Rat acute toxicity2.3261 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9957
hERG inhibition (predictor II)Non-inhibitor0.9362
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Meda pharmaceuticals meda pharmaceuticals inc
  • Able laboratories inc
  • Actavis totowa llc
  • Advent pharmaceuticals inc
  • Aurobindo pharma ltd
  • Concord laboratories inc
  • Corepharma llc
  • Mutual pharmaceutical co inc
  • Pioneer pharmaceuticals inc
  • Sandoz inc
  • Sun pharmaceutical industries ltd
  • Vintage pharmaceuticals inc
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Schering corp sub schering plough corp
Packagers
Dosage forms
FormRouteStrength
Tabletoral
Tabletoral250 mg/1
Tabletoral350 mg/1
Tabletoral350 mg
Prices
Unit descriptionCostUnit
Soma 350 mg tablet5.75USD tablet
Soma Compound 200-325 mg tablet4.58USD tablet
Soma 250 mg tablet3.24USD tablet
Carisoprodol powder1.17USD g
Carisoprodol 350 mg tablet0.57USD tablet
Flexall plus gel0.08USD g
Flexall 16% gel0.06USD g
Flexall 7% gel0.05USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point89-91Berger, F.M. and Ludwig, B.J.; U S . Patent 2,937,119; May 17,1960; assigned to Carter Products, Inc.
water solubility300 mg/L (at 25 °C)MERCK INDEX (1996)
logP2.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.792 mg/mLALOGPS
logP1.76ALOGPS
logP1.92ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)15.06ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area90.65 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity67.1 m3·mol-1ChemAxon
Polarizability28.77 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0a4l-9200000000-84ceb4ca447a62939b63View in MoNA
References
Synthesis Reference

Berger, F.M. and Ludwig, B.J.; U S . Patent 2,937,119; May 17,1960; assigned to Carter
Products, Inc.

General References
  1. Toth PP, Urtis J: Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. Clin Ther. 2004 Sep;26(9):1355-67. [PubMed:15530999 ]
  2. Chou R, Peterson K, Helfand M: Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage. 2004 Aug;28(2):140-75. [PubMed:15276195 ]
  3. Littrell RA, Hayes LR, Stillner V: Carisoprodol (Soma): a new and cautious perspective on an old agent. South Med J. 1993 Jul;86(7):753-6. [PubMed:8322081 ]
External Links
ATC CodesM03BA52M03BA02M03BA72
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (84.9 KB)
MSDSDownload (73.3 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Carisoprodol.
AbirateroneThe metabolism of Carisoprodol can be decreased when combined with Abiraterone.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Carisoprodol.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Carisoprodol.
Acetylsalicylic acidThe serum concentration of the active metabolites of Carisoprodol can be increased when Carisoprodol is used in combination with Acetylsalicylic acid.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Carisoprodol.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Carisoprodol.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Carisoprodol.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Carisoprodol.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Carisoprodol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Carisoprodol.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Carisoprodol.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Carisoprodol.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Carisoprodol.
AmoxapineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Carisoprodol.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Carisoprodol.
ArmodafinilThe metabolism of Carisoprodol can be decreased when combined with Armodafinil.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Carisoprodol.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Carisoprodol.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Carisoprodol.
AzelastineCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Carisoprodol.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Carisoprodol.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Carisoprodol.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Carisoprodol.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Carisoprodol.
BortezomibThe metabolism of Carisoprodol can be decreased when combined with Bortezomib.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.
BrimonidineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Carisoprodol.
BrompheniramineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Carisoprodol.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Carisoprodol.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Carisoprodol.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Carisoprodol.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Carisoprodol.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Carisoprodol.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Carisoprodol.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Carisoprodol.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Carisoprodol.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Carisoprodol.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Carisoprodol.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Carisoprodol.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Carisoprodol.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Carisoprodol.
ChloramphenicolThe metabolism of Carisoprodol can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Carisoprodol.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Carisoprodol.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Carisoprodol.
ChlorphenamineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Carisoprodol.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Carisoprodol.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Carisoprodol.
CholecalciferolThe metabolism of Carisoprodol can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Carisoprodol can be decreased when combined with Cimetidine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Carisoprodol.
CitalopramThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Citalopram.
CitalopramThe metabolism of Carisoprodol can be decreased when combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Carisoprodol.
ClidiniumThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Carisoprodol.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Carisoprodol.
ClomipramineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Carisoprodol.
ClotrimazoleThe metabolism of Carisoprodol can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Carisoprodol.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Carisoprodol.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Carisoprodol.
CyclizineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Carisoprodol.
CyproheptadineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Cyproheptadine.
DabrafenibThe serum concentration of Carisoprodol can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Carisoprodol.
DapoxetineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Dapoxetine.
DelavirdineThe metabolism of Carisoprodol can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Carisoprodol.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Carisoprodol.
DesipramineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Carisoprodol.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Carisoprodol.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Carisoprodol.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Carisoprodol.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Carisoprodol.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Carisoprodol.
DifenoxinThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Carisoprodol.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Carisoprodol.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Carisoprodol.
DimenhydrinateThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Carisoprodol.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Carisoprodol.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Carisoprodol.
DoxepinThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.
DoxylamineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Carisoprodol.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Carisoprodol.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Carisoprodol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Carisoprodol.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Carisoprodol.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Carisoprodol.
EfavirenzThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Carisoprodol.
EntacaponeThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Entacapone.
EscitalopramThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Escitalopram.
Eslicarbazepine acetateThe metabolism of Carisoprodol can be decreased when combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Carisoprodol can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Carisoprodol.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Carisoprodol.
EthanolCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Carisoprodol.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Carisoprodol.
EthosuximideThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Carisoprodol.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Carisoprodol.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Carisoprodol.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Carisoprodol.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Carisoprodol.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Carisoprodol.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Carisoprodol.
EtoperidoneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Carisoprodol.
EtravirineThe metabolism of Carisoprodol can be decreased when combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Carisoprodol.
FenfluramineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Carisoprodol.
FexofenadineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Flibanserin.
FluconazoleThe metabolism of Carisoprodol can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Carisoprodol.
FlunarizineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Carisoprodol.
FluoxetineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Fluoxetine.
FluoxetineThe metabolism of Carisoprodol can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Carisoprodol.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Carisoprodol.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Carisoprodol.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Carisoprodol.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Carisoprodol.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Carisoprodol.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Carisoprodol is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Carisoprodol.
GemfibrozilThe metabolism of Carisoprodol can be decreased when combined with Gemfibrozil.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Carisoprodol.
GuanfacineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Carisoprodol.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Carisoprodol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Carisoprodol.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Carisoprodol.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Carisoprodol.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Carisoprodol.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Carisoprodol.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.
HydroxyzineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Indalpine.
IndinavirThe metabolism of Carisoprodol can be decreased when combined with Indinavir.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Carisoprodol.
IsoniazidThe metabolism of Carisoprodol can be decreased when combined with Isoniazid.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Carisoprodol.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Carisoprodol.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Carisoprodol.
KetoconazoleThe metabolism of Carisoprodol can be decreased when combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Carisoprodol.
LevocabastineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Carisoprodol.
LevomilnacipranThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Carisoprodol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Carisoprodol.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Carisoprodol.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Carisoprodol.
LopinavirThe metabolism of Carisoprodol can be increased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Carisoprodol.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Carisoprodol.
Lu AA21004The risk or severity of adverse effects can be increased when Carisoprodol is combined with Lu AA21004.
LuliconazoleThe serum concentration of Carisoprodol can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Carisoprodol can be decreased when it is combined with Lumacaftor.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Carisoprodol.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Carisoprodol.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Carisoprodol.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Carisoprodol.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Carisoprodol.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Carisoprodol.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Carisoprodol.
MetaxaloneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Carisoprodol.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Carisoprodol.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Carisoprodol.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Carisoprodol.
MethocarbamolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Carisoprodol.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Carisoprodol.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Carisoprodol.
MethsuximideThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Carisoprodol.
MetyrosineCarisoprodol may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Carisoprodol.
MilnacipranThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.
MirtazapineCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Carisoprodol.
MoclobemideThe metabolism of Carisoprodol can be decreased when combined with Moclobemide.
ModafinilThe metabolism of Carisoprodol can be decreased when combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Carisoprodol.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Carisoprodol.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.
NabiloneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Carisoprodol.
NelfinavirThe metabolism of Carisoprodol can be decreased when combined with Nelfinavir.
NicardipineThe metabolism of Carisoprodol can be decreased when combined with Nicardipine.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Carisoprodol.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Carisoprodol.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Carisoprodol.
NortriptylineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Olopatadine.
OmeprazoleThe metabolism of Carisoprodol can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Carisoprodol.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Carisoprodol.
OrphenadrineCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Carisoprodol.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Carisoprodol.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Carisoprodol.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Carisoprodol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Carisoprodol.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Carisoprodol.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Carisoprodol.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Carisoprodol.
PantoprazoleThe metabolism of Carisoprodol can be decreased when combined with Pantoprazole.
ParaldehydeCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Carisoprodol.
ParoxetineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Carisoprodol.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Carisoprodol.
PerampanelThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Carisoprodol.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Carisoprodol.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Carisoprodol.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Carisoprodol.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Carisoprodol.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Carisoprodol.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Carisoprodol.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Carisoprodol.
PipotiazineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Pomalidomide.
PramipexoleCarisoprodol may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Carisoprodol.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Carisoprodol.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Carisoprodol.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Carisoprodol.
PrimidoneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Carisoprodol.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Carisoprodol.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Carisoprodol.
PromethazineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Carisoprodol.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Carisoprodol.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Carisoprodol.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Carisoprodol.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Carisoprodol.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Carisoprodol.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Carisoprodol.
RamelteonThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ramelteon.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Carisoprodol.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Carisoprodol.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Carisoprodol.
RifampicinThe metabolism of Carisoprodol can be increased when combined with Rifampicin.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Carisoprodol.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Carisoprodol.
RopiniroleCarisoprodol may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Carisoprodol.
RotigotineCarisoprodol may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Carisoprodol.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Carisoprodol.
ScopolamineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Carisoprodol.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Carisoprodol.
SertralineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Sertraline.
SertralineThe metabolism of Carisoprodol can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Carisoprodol.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Carisoprodol.
St. John's WortThe serum concentration of the active metabolites of Carisoprodol can be increased when Carisoprodol is used in combination with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Carisoprodol.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Carisoprodol.
SuvorexantThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Tasimelteon.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Carisoprodol.
TetrabenazineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Carisoprodol.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Carisoprodol.
ThalidomideCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Carisoprodol.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Carisoprodol.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Carisoprodol.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Carisoprodol.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Carisoprodol.
TiagabineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Tiagabine.
TiclopidineThe metabolism of Carisoprodol can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Carisoprodol.
TizanidineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Carisoprodol.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Carisoprodol.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Carisoprodol.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Carisoprodol.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Carisoprodol.
TrazodoneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Carisoprodol.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Carisoprodol.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Carisoprodol.
TrimipramineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Carisoprodol.
VigabatrinThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Vilazodone.
VoriconazoleThe metabolism of Carisoprodol can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Carisoprodol.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Carisoprodol.
ZiconotideThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Carisoprodol.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Carisoprodol.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Carisoprodol.
ZonisamideThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Carisoprodol.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Carisoprodol.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Carisoprodol.
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23